Skip to Content

Firstline nivolumab plus ipilimumab shows durable OS after 4 years in patients with pleural mesothelioma

The phase 3 CheckMate 743 study shows prolonged OS for patients with unresectable malignant pleural mesothelioma treated with nivolumab plus ipilimumab vs. chemotherapy. Directly from ESMO 2022, Professor Gerard Zalcman presents the 4-year update of the study, showing that the double immunotherapy continued to provide long-term, durable OS benefit for this group of patients vs. chemotherapy.

Prof. Gerard Zalcman

Få tilgang til artikkelen

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Back to top